CY2039B1 - 5-HT 1-like receptor agonist for rectal administration - Google Patents

5-HT 1-like receptor agonist for rectal administration

Info

Publication number: CY2039B1
Authority: CY; Cyprus
Prior art keywords: pct; receptor agonist; rectal administration; sec; date
Prior art date: 1992-05-07

Application number

CY9802039A

Other languages

English (en)

Original Assignee

Glaxo Lab Sa

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1992-05-07

Filing date

1998-04-30

Publication date

1998-04-30

1998-04-30 Application filed by Glaxo Lab Sa filed Critical Glaxo Lab Sa

1998-04-30 Publication of CY2039B1 publication Critical patent/CY2039B1/xx

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/02—Suppositories; Bougies; Bases therefor; Ovules
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Medicinal Chemistry (AREA)
Pharmacology & Pharmacy (AREA)
Life Sciences & Earth Sciences (AREA)
Animal Behavior & Ethology (AREA)
General Health & Medical Sciences (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Epidemiology (AREA)
Bioinformatics & Cheminformatics (AREA)
Organic Chemistry (AREA)
Pain & Pain Management (AREA)
Biomedical Technology (AREA)
Neurology (AREA)
Neurosurgery (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Engineering & Computer Science (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Medicinal Preparation (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Compositions Of Macromolecular Compounds (AREA)
Plural Heterocyclic Compounds (AREA)
Indole Compounds (AREA)

CY9802039A 1992-05-07 1998-04-30 5-HT 1-like receptor agonist for rectal administration CY2039B1 (en)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
GB929209882A GB9209882D0 (en)	1992-05-07	1992-05-07	Compositions

Publications (1)

Publication Number	Publication Date
CY2039B1 true CY2039B1 (en)	1998-04-30

Family

ID=10715158

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
CY9802039A CY2039B1 (en)	1992-05-07	1998-04-30	5-HT 1-like receptor agonist for rectal administration

Country Status (33)

Country	Link
US (1)	US5705506A (xx)
EP (1)	EP0639072B1 (xx)
JP (1)	JPH07506570A (xx)
KR (1)	KR100253111B1 (xx)
AT (1)	ATE163850T1 (xx)
AU (1)	AU670083B2 (xx)
BE (1)	BE1007024A5 (xx)
BG (1)	BG62120B1 (xx)
BR (1)	BR1100108A (xx)
CA (1)	CA2135179C (xx)
CH (1)	CH685920A5 (xx)
CY (1)	CY2039B1 (xx)
CZ (1)	CZ283512B6 (xx)
DE (1)	DE69317418T2 (xx)
ES (1)	ES2113533T3 (xx)
FR (1)	FR2690847B1 (xx)
GB (2)	GB9209882D0 (xx)
GR (1)	GR3026584T3 (xx)
HK (1)	HK95697A (xx)
HU (2)	HU227338B1 (xx)
IE (1)	IE75203B1 (xx)
IL (1)	IL105468A (xx)
IT (1)	IT1261471B (xx)
NO (1)	NO306700B1 (xx)
NZ (1)	NZ252132A (xx)
OA (1)	OA10109A (xx)
RO (1)	RO112993B1 (xx)
RU (1)	RU2118527C1 (xx)
SG (1)	SG46649A1 (xx)
TW (1)	TW231970B (xx)
UA (1)	UA37206C2 (xx)
WO (1)	WO1993021916A1 (xx)
ZA (1)	ZA933178B (xx)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
WO1997044062A1 (en) *	1996-05-23	1997-11-27	Alcon Laboratories, Inc.	The use of 5-ht1b/1d agonists to treat ocular pain
US7189753B1 (en)	1997-11-06	2007-03-13	Cady Roger K	Preemptive prophylaxis of migraine
ES2219000T3 (es) *	1998-03-26	2004-11-16	Fujisawa Pharmaceutical Co., Ltd.	Preparacion de liberacion sostenida de un compuesto macrolido.
WO2000051624A2 (en) *	1999-03-05	2000-09-08	The Trustees Of University Technology Corporation	Methods and compositions useful in inhibiting apoptosis
AR056690A1 (es) *	2005-10-14	2007-10-17	Athersys Inc	Derivados de indol como inhibidores de indol como inhibidores del receptor 3 de histamina para el tartamiento de trastornos del sueno y cognitivos obesidad y otros trastornos de snc
EP2124556B1 (en)	2006-10-09	2014-09-03	Charleston Laboratories, Inc.	Pharmaceutical compositions
CA2905541C (en)	2008-01-09	2020-02-11	Charleston Laboratories, Inc.	Pharmaceutical compositions comprising an antiemetic and an opioid analgesic
EP3311667A1 (en)	2009-07-08	2018-04-25	Charleston Laboratories, Inc.	Pharmaceutical compositions
EP2627328B1 (en)	2010-10-15	2016-09-14	Contera Pharma APS	Combinations of serotonin receptor agonists for treatment of movement disorders
ES2654787T3 (es)	2012-04-18	2018-02-15	Contera Pharma Aps	Formulación farmacéutica disponible por vía oral adecuada para la gestión mejorada de trastornos del movimiento
WO2017152130A1 (en)	2016-03-04	2017-09-08	Charleston Laboratories, Inc.	Pharmaceutical compositions
JP7227896B2 (ja)	2016-07-11	2023-02-22	コンテラファーマエー／エス	朝の無動状態を治療するための拍動性薬物送達系

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
IT1171450B (it) *	1980-08-12	1987-06-10	Glaxo Group Ltd	Composti eterociclici indolici, procedimento per produrli e composizioni farmaceutiche che li contengono
GB2082175B (en) *	1980-08-12	1984-05-02	Glaxo Group Ltd	Heterocyclic compounds
ZW19381A1 (en) *	1980-08-12	1983-03-09	Glaxo Group Ltd	Heterocyclic compounds
GR79215B (xx) *	1982-06-07	1984-10-22	Glaxo Group Ltd
GB8332435D0 (en) *	1983-12-06	1984-01-11	Glaxo Group Ltd	Chemical compounds
GB2162522B (en) *	1984-08-01	1988-02-24	Glaxo Group Ltd	An indole derivative
GB8419575D0 (en) *	1984-08-01	1984-09-05	Glaxo Group Ltd	Chemical compounds
US4785016A (en) *	1984-12-04	1988-11-15	Glaxo Group Limited	Indole derivatives
GB8431426D0 (en) *	1984-12-13	1985-01-23	Glaxo Group Ltd	Chemical compounds
US4833153A (en) *	1985-11-08	1989-05-23	Glaxo Group Limited	Indole derivatives
PT88255B (pt) *	1987-08-13	1995-03-01	Glaxo Group Ltd	Processo para a preparacao de derivados do indole
AU646871B2 (en) *	1990-06-07	1994-03-10	Astrazeneca Uk Limited	Therapeutic heterocyclic compounds

1992
- 1992-05-07 GB GB929209882A patent/GB9209882D0/en active Pending
1993
- 1993-04-20 IL IL10546893A patent/IL105468A/en not_active IP Right Cessation
- 1993-05-03 EP EP93909884A patent/EP0639072B1/en not_active Expired - Lifetime
- 1993-05-03 HU HU9403188A patent/HU227338B1/hu unknown
- 1993-05-03 WO PCT/EP1993/001077 patent/WO1993021916A1/en not_active Ceased
- 1993-05-03 US US08/331,485 patent/US5705506A/en not_active Expired - Fee Related
- 1993-05-03 UA UA94115989A patent/UA37206C2/uk unknown
- 1993-05-03 CZ CZ942723A patent/CZ283512B6/cs not_active IP Right Cessation
- 1993-05-03 RO RO94-01790A patent/RO112993B1/ro unknown
- 1993-05-03 AU AU40640/93A patent/AU670083B2/en not_active Ceased
- 1993-05-03 DE DE69317418T patent/DE69317418T2/de not_active Expired - Lifetime
- 1993-05-03 RU RU94046069/14A patent/RU2118527C1/ru not_active IP Right Cessation
- 1993-05-03 JP JP5518928A patent/JPH07506570A/ja active Pending
- 1993-05-03 ES ES93909884T patent/ES2113533T3/es not_active Expired - Lifetime
- 1993-05-03 CA CA002135179A patent/CA2135179C/en not_active Expired - Fee Related
- 1993-05-03 NZ NZ252132A patent/NZ252132A/en not_active IP Right Cessation
- 1993-05-03 AT AT93909884T patent/ATE163850T1/de active
- 1993-05-05 SG SG1996007136A patent/SG46649A1/en unknown
- 1993-05-05 GB GB9309209A patent/GB2266665B/en not_active Expired - Lifetime
- 1993-05-06 CH CH139793A patent/CH685920A5/fr not_active IP Right Cessation
- 1993-05-06 IT ITRM930286A patent/IT1261471B/it active IP Right Grant
- 1993-05-06 ZA ZA933178A patent/ZA933178B/xx unknown
- 1993-05-06 IE IE930339A patent/IE75203B1/en not_active IP Right Cessation
- 1993-05-06 FR FR9305432A patent/FR2690847B1/fr not_active Expired - Lifetime
- 1993-05-06 BE BE9300467A patent/BE1007024A5/fr not_active IP Right Cessation
- 1993-05-12 TW TW082103742A patent/TW231970B/zh active
1994
- 1994-11-04 NO NO944214A patent/NO306700B1/no not_active IP Right Cessation
- 1994-11-04 OA OA60578A patent/OA10109A/en unknown
- 1994-11-05 KR KR1019940703950A patent/KR100253111B1/ko not_active Expired - Fee Related
- 1994-11-07 BG BG99167A patent/BG62120B1/bg unknown
1995
- 1995-06-29 HU HU95P/P00531P patent/HU211638A9/hu unknown
1996
- 1996-12-24 BR BR1100108-9A patent/BR1100108A/pt active IP Right Grant
1997
- 1997-06-26 HK HK95697A patent/HK95697A/xx not_active IP Right Cessation
1998
- 1998-04-10 GR GR980400773T patent/GR3026584T3/el unknown
- 1998-04-30 CY CY9802039A patent/CY2039B1/xx unknown

Also Published As

Publication number	Publication date
RU2118527C1 (ru)	1998-09-10
HU227338B1 (en)	2011-04-28
FR2690847B1 (fr)	1995-06-09
SG46649A1 (en)	1998-02-20
IE75203B1 (en)	1997-08-27
WO1993021916A1 (en)	1993-11-11
TW231970B (xx)	1994-10-11
GB2266665A (en)	1993-11-10
CA2135179A1 (en)	1993-11-11
BG99167A (bg)	1995-06-30
CA2135179C (en)	2000-12-05
BG62120B1 (bg)	1999-03-31
GB9309209D0 (en)	1993-06-16
FR2690847A1 (fr)	1993-11-12
HK95697A (en)	1997-08-08
GB2266665B (en)	1996-05-22
DE69317418T2 (de)	1998-07-30
GB9209882D0 (en)	1992-06-24
CH685920A5 (fr)	1995-11-15
ITRM930286A0 (it)	1993-05-06
IE930339A1 (en)	1993-11-17
CZ283512B6 (cs)	1998-04-15
CZ272394A3 (en)	1995-10-18
GR3026584T3 (en)	1998-07-31
KR100253111B1 (en)	2000-07-01
OA10109A (en)	1996-12-18
BE1007024A5 (fr)	1995-02-21
DE69317418D1 (de)	1998-04-16
IL105468A (en)	1998-09-24
HUT71418A (en)	1995-11-28
BR1100108A (pt)	1999-12-07
ZA933178B (en)	1994-01-10
RO112993B1 (ro)	1998-03-30
JPH07506570A (ja)	1995-07-20
HU211638A9 (en)	1995-12-28
NO306700B1 (no)	1999-12-13
NZ252132A (en)	1996-09-25
AU670083B2 (en)	1996-07-04
EP0639072B1 (en)	1998-03-11
ES2113533T3 (es)	1998-05-01
UA37206C2 (uk)	2001-05-15
AU4064093A (en)	1993-11-29
NO944214D0 (no)	1994-11-04
US5705506A (en)	1998-01-06
EP0639072A1 (en)	1995-02-22
NO944214L (no)	1994-11-07
IT1261471B (it)	1996-05-23
ATE163850T1 (de)	1998-03-15
IL105468A0 (en)	1993-08-18
ITRM930286A1 (it)	1994-11-06

Publication	Publication Date	Title
MX9702865A (es)	1998-05-31	Agentes estrogenicos.
EP0903349A3 (en)	2000-05-24	CCR-3 receptor antagonists
MY141384A (en)	2010-04-30	Prevention of loss and restoration of bone mass by certain prostaglandin agonists
IL127244A (en)	2005-11-20	Substituted amines, methods of their preparation and pharmaceutical compositions containing them
ZA971279B (en)	1998-08-14	Use of 5ht4 receptor antagonists for overcoming gastrointestinal effects of serotonin reuptake inhinitors
EA200000299A1 (ru)	2000-12-25	Лекарства
AP2001002129A0 (en)	2001-06-30	5HT1 receptor agonists and metoclopramide for the treatment of migrane.
AU5879299A (en)	2000-05-08	Adenine derivatives
CY2039B1 (en)	1998-04-30	5-HT 1-like receptor agonist for rectal administration
ES2160949T3 (es)	2001-11-16	Derivados de fenilen-sulfonamida sustituidos en meta.
NZ333385A (en)	2000-09-29	Solid oral dosage forms containing 35% of valsartan
AP1424A (en)	2005-06-06	2-Phenyl-1-[4-(2-aminoethoxy)-benzyl]-indole in combination with estrogens.
MXPA03000548A (es)	2004-04-05	Combinacion novedosa de agonista (5-ht2) y antagonistas (5-ht6) de serotonina como formulacion farmaceutica.
SG188700A1 (en)	2013-04-30	Use of at-1 receptor antagonist or at-2 receptor modulator for treating diseases associated with an increase of at-1 or at-2 receptors
GR3030919T3 (en)	1999-11-30	Selective system scan for multizone radiotelephone subscriber units.
GR3022615T3 (en)	1997-05-31	Pharmaceutical compositions based on ebastime or analogues thereof.
WO2000000198A8 (en)	2000-03-23	Piperidine derivatives having effects on serotonin related systems
NZ331683A (en)	2000-01-28	New indole and indazole compounds, a process for their preparation and pharmaceutical compositions containing them
GR3036195T3 (en)	2001-10-31	Novel compounds
BG102229A (en)	1998-09-30	Endothelium receptor antagonists
TW371661B (en)	1999-10-11	Novel intermediates and their use to prepare N,N'-bridged bisindolylmaleimides
GR3026346T3 (en)	1998-06-30	Pharmaceutical compositions comprising contignasterol compounds.
EP1051994A3 (en)	2003-01-08	5HT1 receptor agonists and a COX-2 inhibitor for the treatment of migraine
UA30798A (uk)	2000-12-15	Спосіб пролонгованої терапії онкологічних хворих
ES2141671A1 (es)	2000-03-16	Compuesto pirimidinico activo sobre el sistema nervioso central, procedimiento para su preparacion y composiciones farmaceuticas que lo contienen.